Amoy Diagnostics Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 12.36%

Amoy Diagnostics Co Ltd (300685) has an Asset Resilience Ratio of 12.36% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Amoy Diagnostics Co Ltd (300685) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥277.65 Million
≈ $40.63 Million USD Cash + Short-term Investments

Total Assets

CN¥2.25 Billion
≈ $328.69 Million USD All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio Trend (2018–2024)

This chart shows how Amoy Diagnostics Co Ltd's Asset Resilience Ratio has changed over time. See Amoy Diagnostics Co Ltd (300685) shareholders funds for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Amoy Diagnostics Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Amoy Diagnostics Co Ltd (300685) total market value.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥277.65 Million 12.36%
Total Liquid Assets CN¥277.65 Million 12.36%

Asset Resilience Insights

  • Moderate Liquidity: Amoy Diagnostics Co Ltd has 12.36% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company has significant short-term investments, indicating active treasury management.

Amoy Diagnostics Co Ltd Industry Peers by Asset Resilience Ratio

Compare Amoy Diagnostics Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Dr. Lal Path Labs Ltd.
NSE:LALPATHLAB
Diagnostics & Research 43.99%
Shanghai Rendu Biotechnology Co. Ltd. A
SHG:688193
Diagnostics & Research 55.11%
Diagnos Laboratorium Utama PT Tbk
JK:DGNS
Diagnostics & Research 0.32%
Sonic Healthcare Ltd
AU:SHL
Diagnostics & Research 0.13%
Integral Diagnostics Ltd
AU:IDX
Diagnostics & Research 0.03%
Australian Clinical Labs Ltd
AU:ACL
Diagnostics & Research 4.11%
Healius Ltd
AU:HLS
Diagnostics & Research 0.06%
Monash Ivf Group Ltd
AU:MVF
Diagnostics & Research 1.60%

Annual Asset Resilience Ratio for Amoy Diagnostics Co Ltd (2018–2024)

The table below shows the annual Asset Resilience Ratio data for Amoy Diagnostics Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 17.04% CN¥351.89 Million
≈ $51.49 Million
CN¥2.06 Billion
≈ $302.15 Million
-7.20pp
2023-12-31 24.25% CN¥469.12 Million
≈ $68.65 Million
CN¥1.93 Billion
≈ $283.13 Million
+8.54pp
2022-12-31 15.71% CN¥259.30 Million
≈ $37.94 Million
CN¥1.65 Billion
≈ $241.58 Million
-5.08pp
2021-12-31 20.78% CN¥315.85 Million
≈ $46.22 Million
CN¥1.52 Billion
≈ $222.41 Million
-2.80pp
2020-12-31 23.58% CN¥304.86 Million
≈ $44.61 Million
CN¥1.29 Billion
≈ $189.19 Million
+20.71pp
2019-12-31 2.87% CN¥30.06 Million
≈ $4.40 Million
CN¥1.05 Billion
≈ $153.18 Million
+2.86pp
2018-12-31 0.01% CN¥90.36K
≈ $13.22K
CN¥818.75 Million
≈ $119.81 Million
--
pp = percentage points

About Amoy Diagnostics Co Ltd

SHE:300685 China Diagnostics & Research
Market Cap
$1.16 Billion
CN¥7.91 Billion CNY
Market Cap Rank
#8592 Global
#2281 in China
Share Price
CN¥20.20
Change (1 day)
-0.05%
52-Week Range
CN¥19.51 - CN¥25.58
All Time High
CN¥57.70
About

Amoy Diagnostics Co., Ltd. engages in research and development, production, sale, and supporting services of tumor precision medical diagnostic products in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers and advances targeted treatment research in ovarian cancer; AmoyDx comprehensive … Read more